Neoadjuvant and Adjuvant Treatment in Early-Stage NSCLC: Options Are Expanding " An In the Clinic Activity

TARGET AUDIENCE:
This educational activity has been designed to meet the needs of medical, surgical, and radiation oncologists and other clinicians who treat and manage patients with lung cancer.
PROGRAM OVERVIEW:
The introduction of immune checkpoint inhibitors (ICI) into the treatment of non-small cell lung cancer (NSCLC) has changed the treatment paradigm and become the standard of care in advanced stage lung cancer. Recent and ongoing efforts to replicate the remarkable success of immunotherapy with ICIs and biomarker-guided targeted therapy in advanced/metastatic NSCLC to the management of early-stage NSCLC have broken through the lull in the therapeutic landscape in this setting. The ICIs atezolizumab, durvalumab, and nivolumab have gained FDA approval for early-stage NSCLC indications. These additions to the treatment toolbox offer opportunities to delay recurrence and improve clinical outcomes for patients with this challenging malignancy.
Hear Drs. Gainor and Sands discuss their approach to these patients in this interactive video presentation that will focus on improving the utilization of immunotherapy for neoadjuvant and adjuvant treatment, including:

• Factors to consider " staging, molecular testing, patient-related factors, and treatment-related factors
• Principles of patient selection " who can/should and cannot/should not be considered for immunotherapy
• Referring patients to immunotherapy clinical trials
• Managing immunotherapy-associated toxicities
• Review of ongoing clinical trials
LEARNING OBJECTIVES:
Upon completion of this educational activity, participants should be able to:
• Select optimal treatment for patients with early-stage NSCLC based on appropriate staging and patient-/treatment-related factors
• Integrate testing strategies into the treatment planning process for patients with early-stage disease
• Assess evolving data on the use of adjuvant and neoadjuvant immunotherapy for the management of patients with early-stage NSCLC and strategies for optimizing immunotherapy in routine clinical practice